Research / OXBR / Fundamental state Inspectable configuration
State dimensions Filing 0001493152-22-031975 Insurance
Cash RAW Current state valid · history insufficient
Evidence method Level · gp.fundamentals.cash
$2.2M · CORE · NOT_ENOUGH_HISTORY
Net-income growth RAW Current state valid · history insufficient
Evidence method Yoy · gp.fundamentals.net_income
-133.05% · CORE · NOT_ENOUGH_HISTORY
Premium growth RAW Current state valid · history insufficient
Evidence method Yoy · gp.insurance.premiums
59.73% · CORE · NOT_ENOUGH_HISTORY
Revenue growth RAW Current state valid · history insufficient
Evidence method Yoy · gp.fundamentals.revenue
-109.90% · CORE · NOT_ENOUGH_HISTORY
As-filed lineage Fundamental state history Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History 13 states History building
Mar 31, 2022 0/4 normalized Level 3 Jun 30, 2022 0/3 normalized Level 3 Sep 30, 2022 0/4 normalized Level 3 Dec 31, 2022 0/4 normalized Level 3 Jun 30, 2023 0/4 normalized Level 3 Dec 31, 2023 1/3 normalized Level 3 Mar 31, 2024 1/3 normalized Level 3 Jun 30, 2024 1/3 normalized Level 3 Jun 30, 2025 3/3 normalized Level 3 Sep 30, 2025 3/3 normalized Level 3 Dec 31, 2025 3/3 normalized Level 3 Mar 31, 2026 3/3 normalized Level 3 Jun 30, 2026 3/3 normalized Level 3 Period transition
What moved in the state? Earnings Growth Decreased
Previous -82.81%
Current -133.05%
Delta -50.24% Premium Growth Increased
Previous -5.37%
Current 59.73%
Delta 65.10% Revenue Growth Decreased
Previous -37.52%
Current -109.90%
Delta -72.39% Self-history only Previous similar states Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.